Very excited to share the manuscript from the Phase 1 study of PUR3100, our orally-inhaled dihydroergotamine (DHE) formulation being developed for the treatment of acute migraine, published in Headache: The Journal of Headache & Face Pain. https://lnkd.in/dSP8mu8s
Open Access: https://lnkd.in/gmqkNkqH A phase 1 randomized, double-blind study of a dry powder formulation of #DHE (PUR3100) delivered by oral inhalation had fewer side effects than IV DHE in healthy volunteers, & was associated with rapid absorption & #pain relief Sue Bodie, PharmD, Aidan Curran PhD, Aaron C. Gonzalez Nelson PhD, Jason M. Perry BS, Debora C. Manning MPH, Margaret M. Wasilewski MD